RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CitagenixYou've stopped reading and are just ranting. Everybody is acknowledging that there are significant challenges at every stage of the process. I used the words "dead duck", "failure", "struggling" "challenging" in the post you quoted, I see risk and challenges everywhere.
The problem is not just competition from pre-existing drugs and possible new drugs Echelon identify but still in the clinical development process, on the regulatory front, business developments and much more. I dont know if you've noticed but the stock is heavily discounted compared to any reasonable future value from a possible successful drug, there's good reason for that ( beyond your great insight that Legault is an 1diot). Wherever you look there is risk. The question would be, why did you ever think that there wasnt?
The development path Legault identified early this year and which Antibe has started to execute on looks like like a realistic route to value creation if they continue to execute (but with significant risk, imo). That's why I remain invested in Antibe, why are you stil here?
The way you talk it seems like you believe people here have been hiding the idea of risk from you?
CyrolQue wrote: How come no one has anything to say about ATB-346’s pipeline competition and the danger these drugs pose to ATE?
How come nobody talks about the risks? Who’s dreaming exactly?
from Echelon report:
Competitive knee osteoarthritis therapies advancing through Phase II/III testing still includes Centrexion’s CNTX-4975 and Regeneron’s fasinumab: On competitive landscape, we have flagged Centrexion’s transient potential vanilloid 1 receptor-targeted synthetic trans-capsaicin formulation CNTX-4975 as a pain medication that could overlap with ATB-346 (and naproxen) in the knee osteoarthritis market in time, and since our last research update, the firm reported early PK/Phase I data on this drug at the American College of Rheumatology meeting in Chicago in Oct/18, showing that ‘4975 exhibited buprenorphine - like pain relief in a post - surgical rat pain model and with intra - articular injection into a rat knee pain model. But of course, the firm already has reported Phase II human data at the same conference last year, showing in a 172 -patient trial that WOMAC A1 scores improved significantly at both three and six months in comparison to placebo at the higher of two doses tested (1.0 mg). The firm is funding two Phase III knee osteoarthritis trials (650 patients in total) that will assess one - year impact on WOMAC A1 - quantified pain intensity at one-year; data should be available during F2020.
And we are separately tracking Regeneron Pharmaceuticals’ (partnered with Teva [TEVA -NY, NR] & Mitsubishi Tanabe Pharma [4508JP, NR]) nerve growth factor-targeted mAb fasinumab, for which Phase III testing in the 2,845-patient FACT OA1 (data in Q221), the 1,620-patient FACT OA2 trial (data in Q220) and the 3,565-patient FACT LTS & OA1 trial (data in Q120) is ongoing, and for which interim positive 16-week WOMAC data were reported at two distinct fasinumab dosing regimens (1 mg monthly or bimonthly) in a 646-patient Phase II study back in Aug/18. Our ATE model and valuation drives ATB-346 royalty revenue economics from Bayer’s (BAYN-SW, NR) current naproxen market share with branded formulation Aleve and not from any comparative pharmacology from other Phase II/III-stage osteoarthritis pain assets, including but not limited to CNTX-4975 or fasinumab. Moreover, we do not see GI ulceration rate as being as meaningful to achievable market share as could ATB-346’s activity by this measure as compared to naproxen specifically.
PoorOpinion wrote: Nobody is hiding fact. Last 'facts' I brought to this board was was how backwards the analysts sales for Citigenix have gone over the past two years.
1) You started this thread worrying about the original investors returns. If you did your DD you would know It wasnt citigenix that killed their holdings it was the cancelled PhaseI trial. One guy lied about a hep virus infection and disaster! The company lost >90% of its value. It lost the $10million of investment waiting for that trial to successfully finish. It was a dead duck at that point. From that point just survival was a huge achievement and given we are now funded thru to the end of a long Phase II then you could easily say job done. Look at the value they've managed to squeeze out of a dead duck, I'm in the green from slowly accumulating from those darkest days.
2) I actually think Citigenix was more than just a growth opportunity (which so far has failed). If Phase I succeeds they would never have bought Citagenix, they would have just have pushed on with the trial drugs. Its main job has always been as leverage, more so when the market was unlikely to ever just invest in the HS tech after failed Phase I. So again given we are here now funded to the end of Phase II then that strategy succeeded no matter the failure to break into the US market or make you stinking rich.
3) People keep telling you, you bought into a small, provincial, Canadian biotech struggling to stay afloat, thats been the story since the PhaseI failure. You say did your DD, you should know that. You want it to be a highflying, MIT and Harvard run, Californian darling of the stock market. It isnt! It never will be! You're not investing, or bring us the truth, you're dreaming! And given you're attitude your dream seems to have gone sour.
The company executed yesterday on another small hurdle on the path to their still challenging near-term goal of a US/EU deal. It didnt get eff'd up, be grateful for that, I am. That's as much pumping as I'm prepared to do.
CyrolQue wrote:
the least interesting aspect of the company has cost shareholders millions. Mgmt has either lied time and again about Citagenix or just failed to turn the lemon company they bought around. The reason they bought Citagenix is dubious at best and the result was millions lost in dilution and negative cashflow.
I’ll keep on posting the hard and verifiable facts. Not for you, but for the newcomers. They ought to know the other side of the coin that you and many other pumpers are diligently trying to hide. Maybe that will play its tiny bit of a role in motivating ATE mgmt to stop screwing its shareholders.
I don’t blame you. You’re just a sheep blindly following the flock, hoping the shepherd will lead you to the promise land instead of the slaughterhouse.
PoorOpinion wrote: I heard there's a whole bunch of superstar CEO's all queuing up, just waiting to make Cyrol and the rest of us super rich. That's what they're in the game for obviously.
On a day the management execute again on the lead product Cyrol has his eyes on the least interesting aspect of this company yet again.
Goaweigh wrote: And yet here you are with eyes wide open following this group of incompetent managers on a daily basis.
I guess you're just hedging your bets in case these incompetent bozos get lucky and somehow miraculously discover a blockbuster drug platform and the Co. get's bought out for billions of dollars.
So you're not a complete idiot which is good.
But don't fret, I can, with almost absolute certainty, assure you that your dream of Legault getting sacked will happen eventually. Pfizer or Bayer or whoever won't need his services for long and he will probably be very happy to depart with his golden parachute and a large wad of cash.
If things work out I'm thinking he could get sacked sometime next year maybe.
CyrolQue wrote: Yep, I guess you're right. I'm not the type that blidly follows incompetent managers. This I guess is more your style. After all, likes attracts like.
Goaweigh wrote: I feel very sorry for the people who have been here for 5 years and I'm hoping they get fed up and sell me some stock at .20
As far as competition goes, golly you're right, just walk down the pain relief isle of any pharmacy and you can see just how many differant pills you can take for a hurty knee but maybe they'll find a little shelf space for us somewhere, at least that's the dream.
This is very risky, sortof like a biotech in that regard, and I don't think you are emotionally suited for this type of investment.
Maybe try some widows and orphans stocks, things like GE, all blue sky with no downside.